Novavax climbs 9% after clinical trial shows the firm's COVID-19 vaccine is 90% effective

Business Insider

14 Jun 2021 0 shares 1 views

Novavax climbs 9% after clinical trial shows the firm's COVID-19 vaccine is 90% effective

Novavax climbs 9% after clinical trial shows the firm's COVID-19 vaccine is 90% effective

Business Insider

Published 14 Jun 2021

The company aims to file for FDA approval of NVX-CoV2373 in the third quarter of 2021 and is continuing to study the COVID-19 vaccine in adolescents.

You might like

Related news coverage

When can your kid return to school? AIIMS chief answers

MENAFN.com 28 Jun 2021

(MENAFN - NewsBytes) For much of the past one-and half year, children have been unable to attend classes physically at their..

NA Proactive news snapshot: Power REIT, Byrna Technologies, CytoDyn, Progressive Planet Solutions, AIM ImmunoTech UPDATE …
Proactive Investors 21 Jun 2021
NA Proactive news snapshot: CytoDyn, Progressive Planet Solutions, AIM ImmunoTech, Arizona Silver Exploration UPDATE …
Proactive Investors 21 Jun 2021
Novavax says COVID-19 vaccine 90% effective, also tested in combination with influenza jab
Proactive Investors 15 Jun 2021
Novavax says its COVID-19 vaccine is more than 90 per cent effective
SBS 14 Jun 2021

Advertisement

More coverage

Novavax COVID-19 vaccine shows over 90% efficacy in the U.S. late-stage trial

Novavax COVID-19 vaccine shows over 90% efficacy in the U.S. late-stage trial

Invezz 14 Jun 2021

Novavax Inc (NASDAQ: NVAX) said on Monday its candidate COVID-19 vaccine showed 93% efficacy in its U.S. late-stage trial. The..

Novavax COVID-19 vaccine 90.4% effective in clinical trial, company says
Upworthy 14 Jun 2021
NA Proactive news snapshot: PyroGenesis Canada, American Resources, Arizona Silver, PharmaDrug, Candelaria Mining UPDATE ...
Proactive Investors 07 Jun 2021